Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 acute lymphoblastic leukemia protocol

Journal of Clinical Oncology

Volumn 20, Issue 6, 2002, Pages 1677-1682

  Lipshultz, Steven E ^a   Giantris, Amy L ^a   Lipsitz, Stuart R ^a   Dalton, Virginia Kimball ^a   Asselin, Barbara L ^a   Barr, Ronald D ^a   Clavell, Luis A ^a   Hurwitz, Craig A ^a   Moghrabi, Albert ^a   Samson, Yvan ^a   Schorin, Marshall A ^a   Gelber, Richard D ^a   Sallan, Stephen E ^a   Colan, Steven D ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BOLUS INJECTION; CALCULATION; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DILATATION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CARDIOMYOPATHY, DILATED; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; FEMALE; HEART; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 0037087687     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.6.1677     Document Type: Article

References (22)

1. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion
2. Studies on Adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity
3. Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence of cardiotoxicity
4. Decreased cardiac toxicity of doxombicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma
5. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen: A prospective randomized evaluation
6. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
7. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer
8. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91- 01
9. The relation between cumulative anthracycline dose and late cardiotoxicity in survivors of childhood leukemia
10. Abnormalities of cardiac structure and function in HIV-infected children treated with zidovudine
11. Doxorubicin cardiotoxicity in children: Comparison of a consecutive divided daily dose administration schedule with a single dose (rapid) infusion administration
12. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwestern Oncology Group study
13. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: Assessment by endomyocardial biopsy
14. Increased therapeutic index of weekly doxorubicin in the therapy of non-small-cell lung cancer: A prospective, randomized study
15. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer
16. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors
17. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse
18. Doxorubicin: Effect of different schedules on toxicity and anti-tumor efficacy
19. Effect of doxorubicin (DOX) schedule on tumor response and survival in osteosarcoma (OS): Results of sequential trials Coss 86 A-C. SIOP XXVI abstracts
20. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury
21. Dependence of the cytostatic effect of Adriamycin on drug concentration and exposure time in vivo
22. Comparative survival in tissue culture of normal and neoplastic human cells exposed to Adriamycin